Bli medlem
Bli medlem

Du är här


BB BIOTECH AG: BB Biotech AG completed its current share buyback program

BB BIOTECH AG / BB Biotech AG completed its current share buyback program.
Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is
solely responsible for the content of this announcement.
On March 11, 2016, BB Biotech AG completed its current share buyback program
which was initiated on March 19, 2013. During this period a total of 770 000
registered shares were bought back through the second trading line.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Tanja
Chicherio, Tel. +41 44 267 67 00,

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology
and is one of the world's largest investors in this sector. BB Biotech is
listed in Switzerland, Germany and Italy. Its investments are focused on
listed companies that are developing and commercializing novel medical
treatments and cures. BB Biotech's investment selection process is guided by
the fundamental research and analysis of physicians and molecular biologists.
Its Board of Directors has many years of experience in industry and science.


This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation to
update any forward-looking statements as a result of new information, future
events or other factors.

Press Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB BIOTECH AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.